AgingResearch.NewsJoin free

CD38 antigen receptor membrane-modified mesenchymal stem cell-derived extracellular vesicles

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Huazhong University of Science and Technology and 8 more
  • Animals1

Outcomes

2

Cellular senescence

downin human cells1

1 study

  1. CD38 antigen receptor membrane-modified mesenchymal stem cell-derived extracellular vesicles decrease cellular senescence in human cells.

    “reversed the epithelial-mesenchymal transition phenotype, and rejuvenated senescent A549 cells in vitro”

    Cellsin vitro in senescent A549 cells

    Targeting Senescent Alveolar Epithelial Cells Using Engineered Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Pulmonary Fibrosis

    ACS nano21 Feb 2024

More on Cellular senescence

Pulmonary fibrosis

downin mice1

1 study

  1. CD38 antigen receptor membrane-modified mesenchymal stem cell-derived extracellular vesicles decrease pulmonary fibrosis in mice.

    “CD38-ARM-MSC-EVs effectively restored the NAD+ levels, reversed the epithelial-mesenchymal transition phenotype, and rejuvenated senescent A549 cells in vitro, thereby mitigating multiple age-associated phenotypes and alleviating PF in aged mice.”

    Animalsin naturally aged mouse models

    Targeting Senescent Alveolar Epithelial Cells Using Engineered Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Pulmonary Fibrosis

    ACS nano21 Feb 2024

More on Pulmonary fibrosis

Latest

Related